Thelansis

  Osteoarthritis (OA) is a complex condition characterized by progressive musculoskeletal pain and restricted movement, often accompanied by the deterioration of articular cartilage, changes in local bone structure, and the development of osteophytes. This joint disorder manifests differently between men and women, highlighting the importance of recognizing gender dimorphism for both prevention and treatment strategies. These structural and anatomical distinctions can be observed early and later in life, such as the thinner articular cartilage in the distal femur of girls and women compared to boys and men, leading to joint pain, capsule thickening, and osteophyte formation. Approximately 43.3% of individuals experience persistent pain, aching, or stiffness associated with osteoarthritis. The FDA has approved several drugs for the management of osteoarthritis, including Duexis (ibuprofen and famotidine), Mobic (meloxicam), Naprelan (naproxen sodium), Pennsaid (diclofenac sodium t...

  Osteoarthritis (OA) is a multifactorial disease process whereby progressive musculoskeletal pain and limitation in the movement are accompanied by the loss of articular cartilage, sclerotic and cystic changes in local bone, and osteophyte formation. OA is a joint condition whose presentation so differs between men and women in its attributes that both prevention activities and treatment would benefit from recognition of this dimorphism. These structural and anatomic differences between the sexes are observed early and later in life. Articular cartilage of the distal femur is less thick in girls and women than in boys and men—pain in the affected joint, including thickening of the joint capsule and the formation of osteophytes. ~43.3% have pain, aching, or stiffness osteoarthritis on most days. Reports of pain increased with age up to 68% of patients and were higher in blacks than in whites and in women than in men, 47.6% and 37.4%, respectively.   In the US, the total pr...